15,491 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Acquired by Inceptionr LLC

Inceptionr LLC acquired a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 15,491 shares of the life sciences company's stock, valued at approximately $351,000.

Other hedge funds also recently bought and sold shares of the company. Sachem Head Capital Management LP acquired a new position in shares of Integra LifeSciences during the 3rd quarter valued at about $44,153,000. Glenmede Trust Co. NA raised its stake in Integra LifeSciences by 125.9% during the third quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company's stock worth $13,224,000 after purchasing an additional 405,624 shares during the period. Rubric Capital Management LP acquired a new position in Integra LifeSciences in the 3rd quarter valued at about $5,325,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Integra LifeSciences in the 3rd quarter valued at about $4,271,000. Finally, Systematic Financial Management LP increased its holdings in shares of Integra LifeSciences by 53.9% during the 3rd quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company's stock worth $11,115,000 after buying an additional 214,272 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Trading Up 4.1 %

Shares of NASDAQ IART traded up $0.92 during trading on Tuesday, reaching $23.53. The stock had a trading volume of 276,759 shares, compared to its average volume of 1,006,765. The business's 50-day moving average price is $23.80 and its 200-day moving average price is $21.92. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $36.77. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company has a market cap of $1.82 billion, a P/E ratio of -260.47, a PEG ratio of 0.73 and a beta of 1.23.

Remove Ads

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. The company had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business's revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.89 earnings per share. On average, equities research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley started coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.